Company Overview and News

1
Incyte's Jakafi Demand Strong, Label Expansion to Boost Sales

2018-10-11 zacks
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics.
INCY NVS

3
5 Reasons Why Investors Should Bet on Merck (MRK) Stock

2018-10-08 zacks
Kenilworth, NJ based Merck & Co., Inc. (MRK - Free Report) is a research-driven pharmaceutical company and a global leader in the discovery and development of vaccines and pharmaceutical drugs. The company currently makes noteworthy treatments or vaccines for HPV, type 2 diabetes, cancer and HIV among others.
AZN AMGN AZN INCY

324
Stocks To Watch: Spotlight On Banks, Google Hardware And IPOs

2018-10-06 seekingalpha - 4
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
MMS STZ.B PSX WBA ACRX AEE EGC EXXIQ IMGN SBLK WU SODA GPRE EEXXQ UTX EXXI REX SHLDW ADM MLM NIO SHIP QTT HALO LB NVDA MPC BRO ATVI KO BWXT EA SJM INPAP KBR MA DK JPM SBUX GVA WMT LEAF SHLD IP AMZN OMF EXIXQ OMC SAFM BKS YI POL SQ SBLKL INCY FAST BKE STZ SB GME WEB GOOGL PNC CURO ZUO WFCNP PG DAR TRVN GLOP PYPL GS GOGL AVEO WEED DAL WFC MGI C CMCSA COST FMC THO CGC GNK V T PEP FLR SNE TELL

 
Calithera Biosciences Highlights Breadth of Innovative Pipeline at R&D Day

2018-10-05 globenewswire
-Updated response rate of 50% in advanced renal carcinoma treated with CB-839 + cabozantinib -CB-839 clinical trial collaboration with Pfizer -Presentation of INCB001158 data expected in 1H2019 -R&D day hosted today in New York from 8:00 a.m. -10:15 a.m. ET, live webcast available
CALA INCY

1
Calithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE® (palbociclib) and talazoparib in Combination with CB-839

2018-10-05 globenewswire - 1
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced two new clinical trial collaborations to evaluate Pfizer’s palbociclib, also known as IBRANCE®, and the investigational dual-mechanism poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib, each in combination with Calithera’s glutaminase inhibitor CB-839.
CALA INCY

7
Thursday’s Biggest Winners and Losers in the S&P 500

2018-10-04 247wallst
October 4, 2018: The S&P 500 closed down 0.8% at 2,901.59. The DJIA closed down 0.8% at 26,627.89. Separately, the Nasdaq closed down 1.8% at 7,879.51.
STZ.B NDAQ INCY STZ

 
Calithera Biosciences to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference and the Leerink Partners Rare Disease & Oncology Roundtable

2018-09-24 globenewswire
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced its participation at two upcoming healthcare investor conferences in October.
CALA INCY

17
Surviving The Geron Roller Coaster As An Investor

2018-09-19 seekingalpha - 4
In the absence of further evidence, it seems likely that they will be the beneficiaries of a positive continuation decision.
GERN JNJ INCY

5
Agenus Receives Milestone Payment of $5 Million from Incyte

2018-09-18 zacks - 1
Agenus Inc. (AGEN - Free Report) announced that it has received a cash milestone of $5 million from Incyte Corporation (INCY - Free Report) for the initiation of a phase I study of INCAGN2385, an anti-LAG-3 antibody discovered by Agenus. Agenus is also eligible to receive up to $505 million additionally in potential development, regulatory and commercial milestones from Incyte. This is the fourth antibody from the companies’ partnered programs that has advanced into clinical studies.
GILD AGEN INCY

57
Your Daily Pharma Scoop: XBiotech Reports Positive Data, AstraZeneca's New Approval, Novartis' Positive MS Trial

2018-09-17 seekingalpha - 3
XBiotech reported preliminary positive data from an open-label, dose escalation study of Phase 2 trial assessing its bermekimab candidate in moderate to severe atopic dermatitis (AD). On September 13, the share price climbed 28% pre-market on this apparently positive news. However, in spite of two subsequent spikes during the last two days, the share price has not yet fully recovered to its price range before the mid-September slide that wiped off ~50% of its share price between September 6 ($4.
MBRX MOR IRWD REGN AZN MPSYY INCY ARQL GLPG ARDX ACOR AZN MPSYF BIIB XBIT NVS

48
Your Daily Scoop: Foamix Zooms, Pfizer And Merck Report Positive

2018-09-13 seekingalpha - 2
Share price of Foamix Pharmaceuticals (FOMX) had a 54.4% spike on September 11 after-hours on the news of positive topline results of third Phase 3 clinical trial of its FMX101 drug. The candidate is indicated in the treatment of moderate-to-severe acne. The trial is reported to have successfully met both primary and secondary endpoints.
MKGAF OPK GILD INCY KMPH GLPG ACRX IMNP MKGAY NVS ABBV FMI PFE ABBV FOMX

 
Merck Gets Priority Review for Yet Another Keytruda sBLA

2018-09-13 zacks
Merck & Co., Inc. (MRK - Free Report) announced that the FDA has granted priority review to yet another supplemental biologics license application (sBLA) for its PD-L1 inhibitor, Keytruda. In the latest sBLA, Merck is looking for FDA’s approval to get overall survival (OS) data from a pivotal lung cancer study — KEYNOTE-042 study — included on the label of Keytruda. With the FDA granting priority review, a decision is expected on Jan 11, 2019.
AMGN INCY

3
Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars

2018-09-12 zacks
The major pipeline and regulatory updates in the biotech sector over the past week included positive results from Gilead Sciences’ (GILD - Free Report) pipeline candidate filgotinib. Regeneron/Sanofi’s supplemental application for Praluent was also accepted by the FDA.
REGN GILD INCY GLPG FMI SNY

2
Incyte, Foundation Medicine Partner for Companion Diagnostics

2018-09-12 zacks
Incyte Corporation (INCY - Free Report) inked a deal with molecular information company, Foundation Medicine, Inc., for the development, regulatory support and commercialization of companion diagnostics (CDx). The companies will initially focus on the CDx development for Incyte’s fibroblast growth factor receptor (FGFR) 1/2/3 inhibitor, pemigatinib (INCB54828), in patients with cholangiocarcinoma. CDx is a potential new precision oncology treatment option for cholangiocarcinoma.
GILD INCY NVS FMI

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to INCY / Incyte Corp. on message board site Silicon Investor.

Incyte (INCY) Incyte (INCY) Incyte (INCY)
CUSIP: 45337C102